Trial intelligence / Profile preview

High-dose intravenous adenosine for fractional flow reserve assessment

2007-001916-22Phase 4Completed

Sponsor: Manchester University NHS Foundation Trust
Start: Jul 2007
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of adenosine in coronary arteriosclerosis, sponsored by Manchester University NHS Foundation Trust. Primary endpoint: Difference in FFR between adenosine infusion doses. Started Jul 2007; status: completed.

Drugs

adenosine

Conditions

coronary arteriosclerosis

Beyond the preview

Go deeper on 2007-001916-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-001916-22.